Neuroscience and immunology Team

In Bharat’s 3 years here since joining EMD Serono, he has gained expertise in diverse areas, including concept generation and validation of targets, managing cross-functional project teams, and successfully making data-driven decisions. Bharat is driven by a fascination for science and a desire to contribute toward reducing the burden of human diseases.

Matt joined EMD Serono to follow his passion for drug discovery. As a member of Exploratory Immunology, he assists with advancing projects down the pipeline, and has gained experience with in-vitro assay optimization and other techniques/technologies. Outside of his lab work, Matt serves as an environmental health and safety representative for TIP N&I where he participates in audits and inspections of the labs.

Ling has a strong passion for research and since joining EMD Serono in 2016 she has been focusing on developing functional assays to define the mechanism of action of drug candidates. She has made important contributions for numerous projects. Ling is highly motivated to perform research to identify therapeutic targets to treat autoimmune diseases. Ling also appreciates the opportunities provided by TIP N&I to support her career development in clinical biomarker and project management areas.

Chia Chi is an immunologist who is passionate about discovering new medicines for patients with autoimmune disease. She joined TIP N&I in 2013 because of the collegiality and highly collaborative culture. She takes a mechanism-based approach to disease intervention through deep biological understanding and back-translation from bedside to bench.  She leads an exciting discovery project with an international team of talented scientists. Patient-focused drug development is her priority.

Andrew has been a member of the preclinical pharmacology group of Immunology since joining the company in 2014, supporting projects as they move from late preclinical through early clinical trials.  His group is responsible for running experiments with patient samples or disease models to evaluate novel molecules for efficacy and to help with biomarker discovery and implementation.  He has a particular interest in gene expression analysis.​

As a member of preclinical pharmacology group, Aditee is responsible for developing preclinical models for immunology programs in the discovery pipeline. She provides support to better understand basic disease biology, search for new targets, and develop preclinical strategy for early phase projects. What attracted Aditee to EMD was the opportunity to be a part of a global team of scientists and to work toward discovering new drugs for patients suffering from autoimmune diseases.